Kodiak Sciences (KOD)

Its lead investigational therapy is tarcocimab tedromer, also known as tarcocimab or Zenkuda. Tarcocimab is an anti-VEGF therapy built using the ABC platform. VEGF inhibition is a major treatment approach in diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, where abnormal blood vessel growth or leakage damages vision. Kodiak aims to differentiate its candidates through durability and dosing convenience.

The company is also developing KSI-501, a bispecific therapy that combines VEGF inhibition with targeting of interleukin-6, or IL-6. This program is intended to address retinal vascular diseases by going beyond VEGF alone and engaging inflammatory biology that may contribute to disease progression. Another investigational asset, KSI-101, is a high-strength bispecific protein targeting both IL-6 and VEGF.

Kodiak operates in a competitive ophthalmology market that includes large pharmaceutical companies and established anti-VEGF products. Its investment case depends on whether its ABC platform can deliver clinically meaningful durability, safety, and efficacy advantages. Trial results, regulatory interactions, manufacturing execution, and physician confidence in intravitreal medicines are central factors for the company’s prospects.